KRRO
Korro Bio, Inc. NASDAQ Listed Oct 3, 2019$13.34
After hrs
$13.33
-0.07%
Mkt Cap $125.4M
52w Low $5.20
16.1% of range
52w High $55.89
50d MA $12.39
200d MA $18.69
P/E (TTM)
-1.1x
EV/EBITDA
-1.2x
P/B
2.5x
Debt/Equity
0.8x
ROE
-228.0%
P/FCF
-1.0x
RSI (14)
—
ATR (14)
—
Beta
2.43
50d MA
$12.39
200d MA
$18.69
Avg Volume
193.5K
About
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -1.93 | -5.32 | -175.6% | 11.50 | +19.9% | +11.3% | +9.6% | +7.0% | -0.8% | -3.8% | — |
| Nov 12, 2025 | AMC | -2.61 | -1.92 | +26.4% | 31.42 | -77.8% | -79.3% | -80.7% | -80.4% | -80.2% | -79.6% | — |
| Aug 12, 2025 | AMC | -2.54 | -2.74 | -7.9% | 15.99 | +1.9% | +18.4% | +24.3% | +26.7% | +23.3% | +19.7% | — |
| May 7, 2025 | AMC | -2.60 | -2.49 | +4.2% | 13.93 | -1.8% | +10.6% | +11.7% | +14.7% | +11.6% | +1.3% | — |
| Mar 18, 2025 | AMC | -2.33 | -2.26 | +3.0% | 24.17 | +1.0% | -1.9% | -9.4% | -1.7% | -0.6% | -15.7% | — |
| Nov 12, 2024 | AMC | -2.55 | -2.26 | +11.4% | 65.14 | +1.3% | -15.6% | -23.7% | -27.0% | -28.4% | -28.4% | — |
| Aug 13, 2024 | AMC | -2.40 | -2.43 | -1.2% | 36.36 | +3.9% | +9.2% | +24.0% | +20.8% | +19.6% | +16.3% | — |
| May 14, 2024 | AMC | -2.36 | -2.44 | -3.4% | 50.05 | +1.0% | +5.4% | +2.4% | +9.2% | +9.1% | +1.5% | — |
| Mar 29, 2024 | AMC | -2.36 | -25.65 | -986.9% | — | — | — | — | — | — | — | — |
| Nov 2, 2023 | AMC | -17.73 | -15.50 | +12.6% | 14.15 | +2.5% | +6.0% | +9.4% | +74.0% | +192.6% | +190.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | Raymond James | Upgrade | Market Perform → Outperform | — | $11.50 | $13.79 | +19.9% | +11.3% | +9.6% | +7.0% | -0.8% | -3.8% |
| Mar 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.50 | $13.79 | +19.9% | +11.3% | +9.6% | +7.0% | -0.8% | -3.8% |
| Feb 19 | Clear Street | Upgrade | Hold → Buy | — | $11.24 | $11.86 | +5.5% | +4.1% | -1.2% | +0.4% | +6.1% | +8.0% |
| Feb 17 | William Blair | Upgrade | Market Perform → Outperform | — | $11.17 | $11.96 | +7.1% | +2.8% | +0.6% | +4.7% | -0.5% | +1.0% |
| Jan 29 | Chardan Capital | Upgrade | Neutral → Buy | — | $11.69 | $14.80 | +26.6% | +13.9% | +14.0% | +11.6% | +8.6% | +4.9% |
| Jan 29 | Piper Sandler | Upgrade | Neutral → Overweight | — | $11.69 | $14.80 | +26.6% | +13.9% | +14.0% | +11.6% | +8.6% | +4.9% |
| Jan 29 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $11.69 | $14.80 | +26.6% | +13.9% | +14.0% | +11.6% | +8.6% | +4.9% |
| Jan 28 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $10.74 | $11.42 | +6.3% | +8.8% | +23.9% | +24.1% | +21.5% | +18.2% |
| Jan 28 | Oppenheimer | Upgrade | Perform → Outperform | — | $10.74 | $11.42 | +6.3% | +8.8% | +23.9% | +24.1% | +21.5% | +18.2% |
| Nov 14 | Jones Trading | Downgrade | Buy → Hold | — | $6.50 | $5.77 | -11.2% | -6.6% | -5.4% | -4.3% | -1.4% | -7.8% |
Recent Filings
8-K
Unknown — 8-K Filing
Korro's RNA editing platform progress warrants investor attention as a differentiated approach to rare disease treatment; early clinical validation could drive significant upside if the platform proves commercially viable.
Mar 12
8-K · 1.01
! Medium
Korro Bio, Inc. -- 8-K 1.01: Equity Issuance
Korro Bio raised capital through a private placement led by Venrock Healthcare, securing funding from major institutional investors to advance its pipeline while issuing pre-funded warrants exercisable at nominal terms.
Mar 9
Data updated apr 25, 2026 6:03pm
· Source: massive.com